Please use this identifier to cite or link to this item:
https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/1283
Title: | Aripiprazole in autism spectrum disorder: current evidence for use |
Authors: | Bunting, Apphia Feldman, Harriet |
Keywords: | Autistic Spectrum Disorder (ASD) De-prescribing |
Issue Date: | Apr-2023 |
Citation: | Bunting, A., & Feldman, H. (2023). Aripiprazole in autism spectrum disorder: Current evidence for use. BJPsych Advances, 1-5. |
Abstract: | This month's Cochrane Corner meta-analysis evaluates the evidence for the use of aripiprazole in ‘autism spectrum disorders’ – although in fact, outcome measures mainly included subtypes of challenging behaviour and side-effects. Aripiprazole was found to be effective in reducing irritability and hyperactivity, while causing extrapyramidal side-effects and weight gain. Only three trials were included in the review, with two small trials eventually included in the meta-analysis. All trials were conducted in under-18s in the USA, with no requirement for a trial of behavioural management before psychotropic medication, and excluding under-18s with important comorbidities such as medicated attention-deficit hyperactivity disorder. All three studies were sponsored and funded by the manufacturer of aripiprazole. Further, a discontinuation trial showed no evidence of sustained benefit beyond 16 weeks of treatment. |
Description: | Available with an NHS OpenAthens log in for eligible users |
URI: | https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/1283 |
Appears in Collections: | Autistic Spectrum Disorder (ASD) BJPsych Advances publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.